De novo design of protein binders to stabilize monomeric TDP-43 and inhibit its pathological aggregation
Proceedings of the National Academy of Sciences · 2025
DOI: 10.1073/pnas.2505320122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2025. Verfasst von Gangyu Sun und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China. Hauptthemen laut MEDLINE: DNA-Binding Proteins, Protein Aggregation, Pathological. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: MOST | National Key Research and Development Program of China (NKPs), MOST | National Natural Science Foundation of China (NSFC), Science and Technology Commission of Shanghai Municipality (STCSM).
Abstract (Originalsprache)
Pathological aggregation of transactive response DNA binding protein of 43 kDa (TDP-43), primarily driven by its low-complexity domain, is closely associated with various neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). Despite the therapeutic potential of preventing TDP-43 aggregation, no effective small molecule or biomacromolecule therapeutics have been successfully developed so far. Here, we introduce a protein design strategy that yields de novo designed proteins capable of stabilizing the key amyloidogenic region of TDP-43 in its native helical conformation with nanomolar binding affinity. The binding mechanism was further characterized by the NMR and mutagenesis study. More importantly, we demonstrated that our designed protein binders efficiently reduced TDP-43 amyloid aggregation both in vitro and in cells. Our work provides a strategy for designing protein stabilizer of the native conformation of pathological proteins for preventing its amyloid aggregation, shedding light on the development of potential therapeutic approaches for ALS, FTLD, and other protein aggregation-associated diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China.
- Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University, Shanghai 200030, China.
- Zhangjiang Institute for Advanced Study, Shanghai Jiao Tong University, Shanghai 200240, China.
- Interdisciplinary Research Center on Biology and Chemistry, State Key Laboratory of Chemical Biology, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 201210, China.
- Shanghai Academy of Natural Sciences, Fudan University, Shanghai 200433, China.
ORCID-Profile: Gangyu Sun, Xiang Li, Jiaojiao Hu, Cong Liu, Zhizhi Wang, Dan Li
Förderung
- MOST | National Key Research and Development Program of China (NKPs)
- MOST | National Natural Science Foundation of China (NSFC)
- Science and Technology Commission of Shanghai Municipality (STCSM)
- Chinese Academy of Sciences, Shanghai Branch (ä¸ç§'院上海分院)
Zitieren
APA
Sun, G., Li, X., Hu, J., Yang, T., Liu, C., Wang, Z., Li, D., & Xu, W. (2025). De novo design of protein binders to stabilize monomeric TDP-43 and inhibit its pathological aggregation. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2505320122
Vancouver
Sun G, Li X, Hu J, Yang T, Liu C, Wang Z, et al. De novo design of protein binders to stabilize monomeric TDP-43 and inhibit its pathological aggregation. Proceedings of the National Academy of Sciences. 2025. doi:10.1073/pnas.2505320122
BibTeX
@article{Sun2025,
author = {Sun, Gangyu and Li, Xiang and Hu, Jiaojiao and Yang, Tianbin and Liu, Cong and Wang, Zhizhi and Li, Dan and Xu, Wenqing},
title = {De novo design of protein binders to stabilize monomeric TDP-43 and inhibit its pathological aggregation},
journal = {Proceedings of the National Academy of Sciences},
year = {2025},
doi = {10.1073/pnas.2505320122}
}
EUVIMED